Attached files
file | filename |
---|---|
8-K - FORM 8-K - Anthera Pharmaceuticals Inc | f59372e8vk.htm |
EX-5.1 - EX-5.1 - Anthera Pharmaceuticals Inc | f59372exv5w1.htm |
EX-1.1 - EX-1.1 - Anthera Pharmaceuticals Inc | f59372exv1w1.htm |
EX-99.1 - EX-99.1 - Anthera Pharmaceuticals Inc | f59372exv99w1.htm |
Exhibit 99.2
Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
HAYWARD, Calif., June 3, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the
pricing of an underwritten public offering of 6,666,667 shares of its common stock, offered
at a price of $7.50 per share. The offering is expected to close on or about June 8, 2011,
subject to customary closing conditions. In addition, Anthera has granted the underwriters a 30-day
option to purchase up to an additional 1,000,000 shares of common stock to cover
over-allotments, if any. Citi and Leerink Swann LLC are acting as joint book-running managers in
the offering and Canaccord Genuity is acting as lead co-manager in the offering.
The Company estimates that the net proceeds from the offering, after deducting customary
underwriting discounts and commissions and estimated offering expenses, will be approximately
$47 million (or approximately $54 million if the underwriters over-allotment option is
exercised in full). The Company intends to use the net proceeds from the offering for general
corporate purposes.
The securities described above are being offered by the Company pursuant to a shelf registration
statement previously filed with, and declared effective by, the Securities and Exchange Commission
(the SEC) on March 11, 2011. A final prospectus supplement relating to the offering will be
filed with the SEC and will be available on the SECs website at http://www.sec.gov. Copies of the
final prospectus supplement relating to these securities may be obtained from the prospectus
department of Citi, 140 58th Street, 8th Floor, Brooklyn, New York 11220,
Telephone: (800) 831-9146, or by email at batprospectusdept@citi.com. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws of any such state
or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing
products to treat serious diseases associated with inflammation, including cardiovascular and
autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002),
A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel
enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels
of sPLA2 have been implicated in a variety of acute inflammatory conditions, including
acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable
coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF)
which have been associated with a variety of B-Cell mediated autoimmune diseases, including
systemic lupus erythematosus (lupus) and rheumatoid arthritis.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical
matters, including statements that are preceded by, followed by, or that include such words as
estimate, intend, anticipate, believe, plan, goal, expect, project, or similar
statements, are forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These include, but are not limited to,
statements relating to Antheras ability to successfully complete the proposed offering and the use
of proceeds therefrom, as well as other risks that are described in further detail in the
preliminary prospectus supplement relating to the offering and the Companys most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time to time in other
publicly available information regarding the Company. These forward-looking statements are based on
Antheras expectations as of the date of this press release and are subject to certain risks and
uncertainties that could cause actual results to differ materially as set forth in the Companys
public filings with the SEC. Anthera disclaims any intent or obligation to update any
forward-looking statements, whether because of new information, future events or otherwise, except
as required by applicable law.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.
2